Hoth Therapeutics Inc. (HOTH) Announces Proposed Public Offering of Common Stock

Hoth Therapeutics Inc. (Nasdaq: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in a "best efforts" underwritten public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. The Benchmark Company, LLC is serving as Qualified Independent Underwriter for the offering. Hoth intends to use the net proceeds from the offering for general corporate purposes, including the development of products to prevent the COVID-19 virus, working capital, sales and marketing activities, and general and administrative matters.

A shelf registration statement on Form S-3 (Registration No. 333-236887) relating to the public offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (SEC) and declared effective on March 4, 2020.

You May Also Be Interested In

• DSS, Inc. launches public stock offering on NYSE American
• EastGroup Properties reports leasing, acquisitions, and new equity deals
• Bally's CFO resigns; president named interim replacement